All In Biotech

Drug Trial Radar · NCT05725902

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Mar 9, 2024

Primary completion

Mar 9, 2026

Study completion Mar 9, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Conditions

  • Sickle Cell Disease

Interventions

  • EtavopivatDrug

    The study intervention is etavopivat (400 mg), administered orally and once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of etavopivat on cerebral blood flow (CBF)Time frame: 24 weeks
  2. Effect of etavopivat on oxygen ejection fraction (OEF)Time frame: 24 weeks
  3. Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Children's Healthcare of Atlanta

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.